Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 16/20 | 0.63 |
| ▸ | NMBR | P28336 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30312757 | 1.00 | GRPR (0.63) | GRPRNMBR | |
| SCHEMBL5350846 | 0.92 | GRPR (0.66) | GRPRNMBR | |
| SCHEMBL16508339 | 0.92 | GRPR (0.69) | GRPR | |
| SCHEMBL19102240 | 0.92 | GRPR (0.69) | GRPR | |
| SCHEMBL4353658 | 0.91 | GRPR (0.62) | GRPR | |
| SCHEMBL4353652 | 0.91 | GRPR (0.62) | GRPR | |
| SCHEMBL1413933 | 0.91 | GRPR (0.68) | GRPR | |
| SCHEMBL1413932 | 0.91 | GRPR (0.68) | GRPR | |
| SCHEMBL4352525 | 0.91 | GRPR (0.67) | GRPR | |
| SCHEMBL4352522 | 0.91 | GRPR (0.67) | GRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099249-A1 | MODIFIED AND UNMODIFIED PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN SUBJECTS HAVING INCREASED AMYLOID-BETA AND/OR PHOSPHO-TAU-PROTEIN LOAD AND/OR NEUROINFLAMMATION | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20230149516-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | PAM THERAGNOSTICS GMBH (DE) | 2023-05-18 | — | — | US | claimed |
| US-20230097988-A1 | METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE | PAM THERAGNOSTICS GMBH (DE) | 2023-03-30 | — | — | US | claimed |
| EP-4111201-A1 | METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| EP-4110372-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| WO-2026099243-A1 | MODIFIED AND UNMODIFIED PEPTIDYL-GLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN THE TREATMENT OR PREVENTION OF CEREBRAL HYPOPERFUSION FOR THE IMPROVEMENT OF CEREBRAL BLOOD FLOW (CBF) | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026099249-A1 | MODIFIED AND UNMODIFIED PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN SUBJECTS HAVING INCREASED AMYLOID-BETA AND/OR PHOSPHO-TAU-PROTEIN LOAD AND/OR NEUROINFLAMMATION | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | disclosed |
| EP-3908840-B1 | HIGHLY SELECTIVE AND ULTRASENSITIVE METAL ION SENSOR | AMILION TECH AB (SE) | 2026-03-04 | — | — | EP | disclosed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2025227105-A1 | CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250223580-A1 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | THE BROAD INSTITUTE, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| WO-2022212362-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022186782-A1 | METHODS FOR CYCLIZATION OF (POLY)PEPTIDES COMPRISING Nγ-HYDROXY- OR Nγ-AMINO-L-ASPARAGINE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-09-09 | — | — | WO | disclosed |
| EP-4037715-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
| US-20220213461-A1 | ASX-SPECIFIC PROTEIN LIGASES AND USES THEREOF | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-07-07 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-20220099548-A1 | HIGHLY SELECTIVE AND ULTRASENSITIVE METAL ION SENSOR | AMILION TECHNOLOGY AB (SE) | 2022-03-31 | — | — | US | disclosed |
| CN-106459160-B | ASX-specific protein ligases | 南洋理工大学 | 2022-03-29 | — | — | CN | disclosed |
| EP-3966321-A1 | ASX-SPECIFIC PROTEIN LIGASES AND USES THEREOF | Nanyang Technological University (SG) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | GRPR 936/4885NMBR 1416/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | GRPR 641/4885NMBR 1408/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | GRPR 936/4885NMBR 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.